Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing’s Disease

Author(s): Andreea Liliana Serban, Benedetta Zampetti, Andrea Saladino, Vittoria Favero*, Iacopo Chiodini and Renato Cozzi

Volume 24, Issue 7, 2024

Published on: 03 November, 2023

Page: [845 - 849] Pages: 5

DOI: 10.2174/0118715303260160231020070423

Price: $65

Abstract

Background: Pasireotide is a multireceptor somatostatin analogue approved for the treatment of patients with Cushing's disease (CD) who are ineligible or poor candidates for pituitary surgery. Here we present a patient with severe recurrent CD who was treated with pasiretide and showed opposite results between hormonal levels and pituitary tumour size.

Case Presentation: A 54-year-old woman was diagnosed with CD, a first surgical transsphenoidal procedure was performed at the time of diagnosis, and the disease recurred seven years later. She underwent a second transsphenoidal surgery, but despite apparent complete removal of the adenoma, the hypercortisolism worsened. Magnetic resonance imaging showed a tiny remnant of the adenoma adjacent to the cavernous sinus, and ketoconazole was started at a dose of 800 mg/day. Due to the persistence of pathological urinary free cortisol levels, 600 μg bid pasireotide was added. The combination therapy induced first normalisation of urinary free cortisol and later hypoadrenalism, so that ketoconazole was discontinued and pasireotide was maintained. A marked clinical improvement was achieved with pasireotide. Adrenal insufficiency persisted despite progressive tapering of the pasireotide dose to 150 mg once daily. Pituitary magnetic resonance imaging performed at 12 and 24 months during low-dose pasireotide treatment showed a few millimetres increase of the remnant.

Conclusions: This report suggests that CD Pas induces an opposite effect between hormonal profile and increase of pituitary tumor size. This peculiar phenomenon may be a consequence of the unusually low doses of pasireotide needed to control hormonal hypersecretion.

Keywords: Cushing’s disease, pasireotide, cushing’s syndrome, somatostatin receptors, corticotroph adenoma, tumor growth.

« Previous Next »
Graphical Abstract

[1]
Fleseriu, M.; Iweha, C.; Salgado, L.; Mazzuco, T.L.; Campigotto, F.; Maamari, R.; Limumpornpetch, P. Safety and efficacy of subcutaneous pasireotide in patients with cushing’s disease: Results from an open-label, multicenter, single-arm, multinational, expanded-access study. Front. Endocrinol., 2019, 10, 436.
[http://dx.doi.org/10.3389/fendo.2019.00436] [PMID: 31379734]
[2]
Lacroix, A.; Gu, F.; Schopohl, J.; Kandra, A.; Pedroncelli, A.M.; Jin, L.; Pivonello, R. Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: Results from a Phase 3 study. Pituitary, 2020, 23(3), 203-211.
[http://dx.doi.org/10.1007/s11102-019-01021-2] [PMID: 31875276]
[3]
Biller, B.M.K.; Grossman, A.B.; Stewart, P.M.; Melmed, S.; Bertagna, X.; Bertherat, J.; Buchfelder, M.; Colao, A.; Hermus, A.R.; Hofland, L.J.; Klibanski, A.; Lacroix, A.; Lindsay, J.R.; Newell-Price, J.; Nieman, L.K.; Petersenn, S.; Sonino, N.; Stalla, G.K.; Swearingen, B.; Vance, M.L.; Wass, J.A.H.; Boscaro, M. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: A consensus statement. J. Clin. Endocrinol. Metab., 2008, 93(7), 2454-2462.
[http://dx.doi.org/10.1210/jc.2007-2734] [PMID: 18413427]
[4]
Stroud, A.; Dhaliwal, P.; Alvarado, R.; Winder, M.J.; Jonker, B.P.; Grayson, J.W.; Hamizan, A.; Harvey, R.J.; McCormack, A. Outcomes of pituitary surgery for Cushing’s disease: A systematic review and meta-analysis. Pituitary, 2020, 23(5), 595-609.
[http://dx.doi.org/10.1007/s11102-020-01066-8] [PMID: 32691356]
[5]
Serban, A.L.; Del Sindaco, G.; Sala, E.; Carosi, G.; Indirli, R.; Rodari, G.; Giavoli, C.; Locatelli, M.; Carrabba, G.; Bertani, G.; Marfia, G.; Mantovani, G.; Arosio, M.; Ferrante, E. Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. J. Endocrinol. Invest., 2020, 43(5), 631-639.
[http://dx.doi.org/10.1007/s40618-019-01151-1] [PMID: 31773581]
[6]
Patil, C.G.; Veeravagu, A.; Prevedello, D.M.; Katznelson, L.; Vance, M.L.; Laws, E.R., Jr Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery, 2008, 63(2), 266-270.
[http://dx.doi.org/10.1227/01.NEU.0000313117.35824.9F] [PMID: 18797356]
[7]
Pivonello, R.; Ferrigno, R.; De Martino, M.C.; Simeoli, C.; Di Paola, N.; Pivonello, C.; Barba, L.; Negri, M.; De Angelis, C.; Colao, A. Medical treatment of cushing’s disease: An overview of the current and recent clinical trials. Front. Endocrinol., 2020, 11, 648.
[http://dx.doi.org/10.3389/fendo.2020.00648] [PMID: 33363514]
[8]
Colao, A.; Petersenn, S.; Newell-Price, J.; Findling, J.W.; Gu, F.; Maldonado, M.; Schoenherr, U.; Mills, D.; Salgado, L.R.; Biller, B.M. A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med., 2012, 366(10), 914-924.
[http://dx.doi.org/10.1056/NEJMoa1105743] [PMID: 22397653]
[9]
Duggan, S. Osilodrostat: First approval. Drugs, 2020, 80(5), 495-500.
[http://dx.doi.org/10.1007/s40265-020-01277-0] [PMID: 32141023]
[10]
Pivonello, R.; Bancos, I.; Feelders, R.A.; Kargi, A.Y.; Kerr, J.M.; Gordon, M.B.; Mariash, C.N.; Terzolo, M.; Ellison, N.; Moraitis, A.G. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: Results from a prospective, open-label phase 2 study. Front. Endocrinol., 2021, 12, 662865.
[http://dx.doi.org/10.3389/fendo.2021.662865] [PMID: 34335465]
[11]
Bolanowski, M. Kałużny, M.; Witek, P.; Jawiarczyk-Przybyłowska, A. Pasireotide: A novel somatostatin receptor ligand after 20 years of use. Rev. Endocr. Metab. Disord., 2022, 23(3), 601-620.
[http://dx.doi.org/10.1007/s11154-022-09710-3] [PMID: 35067849]
[12]
Alexandraki, K.I.; Grossman, A.B. Therapeutic strategies for the treatment of severe cushing’s syndrome. Drugs, 2016, 76(4), 447-458.
[http://dx.doi.org/10.1007/s40265-016-0539-6] [PMID: 26833215]
[13]
Yamamoto, M.; Nakao, T.; Ogawa, W.; Fukuoka, H. Aggressive cushing’s disease: Molecular pathology and its therapeutic approach. Front. Endocrinol., 2021, 12, 650791.
[http://dx.doi.org/10.3389/fendo.2021.650791] [PMID: 34220707]
[14]
Lacroix, A.; Gu, F.; Gallardo, W.; Pivonello, R.; Yu, Y.; Witek, P.; Boscaro, M.; Salvatori, R.; Yamada, M.; Tauchmanova, L.; Roughton, M.; Ravichandran, S.; Petersenn, S.; Biller, B.M.K.; Newell-Price, J.; Arnaldi, G.; Asha, H.S.; Bandgar, T.; Barkan, A.; Biering, H.; Bex, M.; Bolanowski, M.; Bronstein, M.D.; Brue, T.; Bruera, D.; Cavagnini, F.; Comlekci, A.; De Block, C.; Delibasi, T.; Fajardo-Montañana, C.; Feelders, R.A.; Fleseriu, M.; Gadelha, M.R.; Geer, E.B.; Heaney, A.; Houde, G.; Ichihara, A.; Imran, S.A.; Ioachimescu, A.; Kadioglu, P.; Li, Y.; Loli, P.; Nishiyama, M.; Rozhinskaya, L.; Ruchala, M.; Saitoh, Y.; Schöfl, C.; Schopohl, J.; Shimatsu, A.; Shimizu, C.; Snabboon, T.; Snyder, P.; Suzaki, N.; Tabarin, A.; Takahashi, Y.; Britto, S.T. T’Sjoen, G.; Vantyghem, M-C.; Velkeniers, B.; Webb, S.; Yamada, S. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: A 12 month clinical trial. Lancet Diabetes Endocrinol., 2018, 6(1), 17-26.
[http://dx.doi.org/10.1016/S2213-8587(17)30326-1] [PMID: 29032078]
[15]
Colao, A.; De Block, C.; Gaztambide, M.S.; Kumar, S.; Seufert, J.; Casanueva, F.F. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: Medical expert recommendations. Pituitary, 2014, 17(2), 180-186.
[http://dx.doi.org/10.1007/s11102-013-0483-3] [PMID: 23564338]
[16]
Grossrubatscher, E.; Zampetti, B.; Dalino, C.P.; Doneda, P.; Loli, P. Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test. Clin. Case Rep., 2015, 3(8), 718-722.
[http://dx.doi.org/10.1002/ccr3.321] [PMID: 26331021]
[17]
Trementino, L.; Cardinaletti, M.; Concettoni, C.; Marcelli, G.; Boscaro, M.; Arnaldi, G. Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: Literature review and clinical practice considerations. Pituitary, 2015, 18(3), 359-365.
[http://dx.doi.org/10.1007/s11102-014-0582-9] [PMID: 24952218]
[18]
Wong, M.; Malabu, U.H.; Korah, I; Tan, Y. Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose? Endocrinol. Diabetes Metab. Case Rep, 2021, 20– 0206, EDM200206.
[http://dx.doi.org/10.1530/EDM-20-0206]
[19]
Adams, R.L.; Adams, I.P.; Lindow, S.W.; Atkin, S.L. Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin. Endocrinol., 2004, 61(4), 431-436.
[http://dx.doi.org/10.1111/j.1365-2265.2004.02098.x] [PMID: 15473874]
[20]
Zatelli, M.C.; Piccin, D.; Vignali, C.; Tagliati, F.; Ambrosio, M.R.; Bondanelli, M.; Cimino, V.; Bianchi, A.; Schmid, H.A.; Scanarini, M.; Pontecorvi, A.; De Marinis, L.; Maira, G. degli Uberti, E.C. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer, 2007, 14(1), 91-102.
[http://dx.doi.org/10.1677/ERC-06-0026] [PMID: 17395978]
[21]
Gatto, F.; Arvigo, M.; Amarù, J.; Campana, C.; Cocchiara, F.; Graziani, G.; Bruzzone, E.; Giusti, M.; Boschetti, M.; Ferone, D. Cell specific interaction of pasireotide: Review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary, 2019, 22(1), 89-99.
[http://dx.doi.org/10.1007/s11102-018-0926-y] [PMID: 30483918]
[22]
Pivonello, R.; Munster, P.N.; Terzolo, M.; Ferrigno, R.; Simeoli, C.; Puglisi, S.; Bali, U.; Moraitis, A.G. Glucocorticoid receptor antagonism upregulates somatostatin receptor subtype 2 expression in acth-producing neuroendocrine tumors: New insight based on the selective glucocorticoid receptor modulator relacorilant. Front. Endocrinol., 2022, 12, 793262.
[http://dx.doi.org/10.3389/fendo.2021.793262] [PMID: 35058882]
[23]
Daniel, E.; Newell-Price, J. Recent advances in understanding Cushing disease: Resistance to glucocorticoid negative feedback and somatic USP8 mutations. F1000 Res., 2017, 6, 613.
[http://dx.doi.org/10.12688/f1000research.10968.1] [PMID: 28529722]
[24]
Albani, A.; Perez-Rivas, L.G.; Tang, S.; Simon, J.; Lucia, K.E.; Colón-Bolea, P.; Schopohl, J.; Roeber, S.; Buchfelder, M.; Rotermund, R.; Flitsch, J.; Thorsteinsdottir, J.; Herms, J.; Stalla, G.; Reincke, M.; Theodoropoulou, M. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr. Relat. Cancer, 2022, 29(8), 503-511.
[http://dx.doi.org/10.1530/ERC-22-0088] [PMID: 35686696]

Rights & Permissions Print Cite
Article Metrics
24
2
© 2024 Bentham Science Publishers | Privacy Policy